Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 13/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.34 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.34 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642636 | 0.81 | ACVRL1 (0.42) | ADKACVRL1MTORRICTORRPTOR | |
| SCHEMBL10101592 | 0.80 | DOT1L (0.44) | ACVRL1PIK3CD | |
| SCHEMBL10101562 | 0.80 | ACVRL1 (0.40) | ACVRL1 | |
| SCHEMBL10101558 | 0.80 | ADK (0.35) | ADKACVRL1PIK3CD | |
| SCHEMBL10101568 | 0.80 | PIK3CD (0.36) | ACVRL1PIK3CD | |
| SCHEMBL10101597 | 0.80 | ADK (0.45) | ADKACVRL1PIK3CD | |
| SCHEMBL10101583 | 0.78 | NPC1 (0.40) | ACVRL1 | |
| SCHEMBL10101588 | 0.78 | HIF1A (0.35) | ADKACVRL1 | |
| SCHEMBL10101578 | 0.78 | KDM4E (0.36) | ADKACVRL1PIK3CD | |
| SCHEMBL10101611 | 0.78 | DOT1L (0.40) | ADKACVRL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | disclosed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ADK 72/4885ACVRL1 4215/4885MTOR 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.